Ascentage Pharma announces IND clearance by the China CDE for APG-3288

Ascentage Pharma (AAPG) “announced that its novel next-generation Bruton’s tyrosine kinase-targeted protein degrader, APG-3288, has received investigational new drug application clearance from the China Center for Drug Evaluation and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE, which came shortly after the IND was cleared by the U.S. Food and Drug Administration, ushers in a new phase in the multicenter clinical development of APG-3288 and highlights Ascentage Pharma’s robust global development capabilities in the field of targeted protein degradation. Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.”